Literature DB >> 25906382

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.

Enrico Franceschi1, Alba A Brandes.   

Abstract

Entities:  

Keywords:  bevacizumab; glioblastoma; survival

Mesh：

Substances：

Year:  2015        PMID： 25906382      PMCID： PMC6088337          DOI： 10.2217/cns.15.7

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


× No keyword cloud information.
  15 in total

Review 1.  Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma.

Authors:  A A Brandes; E Franceschi; T Gorlia; W Wick; A H Jacobs; B G Baumert; M van den Bent; M Weller; R Stupp
Journal:  Eur J Cancer       Date:  2011-11-24       Impact factor: 9.162

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

Review 3.  Practical management of bevacizumab-related toxicities in glioblastoma.

Authors:  Alba A Brandes; Marco Bartolotti; Alicia Tosoni; Rosalba Poggi; Enrico Franceschi
Journal:  Oncologist       Date:  2015-01-07

4.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Authors:  M Brada; K Hoang-Xuan; R Rampling; P Y Dietrich; L Y Dirix; D Macdonald; J J Heimans; B A Zonnenberg; J M Bravo-Marques; R Henriksson; R Stupp; N Yue; J Bruner; M Dugan; S Rao; S Zaknoen
Journal:  Ann Oncol       Date:  2001-02       Impact factor: 32.976

5.  Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

Authors:  Michael Prados; Timothy Cloughesy; Meghna Samant; Liang Fang; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Asha Das; Henry S Friedman
Journal:  Neuro Oncol       Date:  2010-11-17       Impact factor: 12.300

6.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

7.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

8.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Paul Mulholland; Bart Neyns; L Burt Nabors; Mario Campone; Antje Wick; Warren Mason; Tom Mikkelsen; Surasak Phuphanich; Lynn S Ashby; John Degroot; Rao Gattamaneni; Lawrence Cher; Mark Rosenthal; Franz Payer; Juliane M Jürgensmeier; Rakesh K Jain; A Gregory Sorensen; John Xu; Qi Liu; Martin van den Bent
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544

9.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.

Authors:  Kelong Han; Melanie Ren; Wolfgang Wick; Lauren Abrey; Asha Das; Jin Jin; David A Reardon
Journal:  Neuro Oncol       Date:  2013-12-12       Impact factor: 12.300
View more
  2 in total

Review 1.  Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.

Authors:  Alicia Tosoni; Enrico Franceschi; Rosalba Poggi; Alba A Brandes
Journal:  Curr Treat Options Oncol       Date:  2016-09

2.  Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model.

Authors:  Etienne Audureau; Anaïs Chivet; Renata Ursu; Robert Corns; Philippe Metellus; Georges Noel; Sonia Zouaoui; Jacques Guyotat; Pierre-Jean Le Reste; Thierry Faillot; Fabien Litre; Nicolas Desse; Antoine Petit; Evelyne Emery; Emmanuelle Lechapt-Zalcman; Johann Peltier; Julien Duntze; Edouard Dezamis; Jimmy Voirin; Philippe Menei; François Caire; Phong Dam Hieu; Jean-Luc Barat; Olivier Langlois; Jean-Rodolphe Vignes; Pascale Fabbro-Peray; Adeline Riondel; Elodie Sorbets; Marc Zanello; Alexandre Roux; Antoine Carpentier; Luc Bauchet; Johan Pallud
Journal:  J Neurooncol       Date:  2017-11-20       Impact factor: 4.130
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.